Product Description
Mechanisms of Action: 5-HT2A Antagonist, GPIIb/IIIa Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: India | Korea
Approved Indications: None
Known Adverse Events: None
Company: Daewoong
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Peripheral Vascular Diseases|Myocardial Ischemia|Coronary Artery Disease|Peripheral Arterial Disease|Angina Pectoris, Variant|Kidney Failure, Chronic|Diabetic Nephropathy|Kidney Diseases|Intermittent Claudication|Thrombophilia|Arterial Occlusive Diseases
Phase 3: Peripheral Arterial Disease|Peripheral Vascular Diseases|Ischemic Stroke|Coronary Artery Disease|Kidney Failure, Chronic
Phase 1: Healthy Volunteers|Malnutrition|Chronic Pain|Hypertension|Peripheral Arterial Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06424548 |
SEUMC 2023-10-009 | N/A |
Not yet recruiting |
Stroke|Atherosclerosis|Intermittent Claudication |
2028-06-30 |
2024-10-16 |
Primary Endpoints|Treatments |
|
NCT05730621 |
YMC047 | P4 |
Completed |
Peripheral Arterial Disease|Myocardial Ischemia|Peripheral Vascular Diseases|Coronary Artery Disease |
2024-02-28 |
2024-11-22 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
|
NCT06046196 |
YMC044 | P4 |
Completed |
Arterial Occlusive Diseases|Intermittent Claudication |
2023-03-09 |
2024-10-16 |
Primary Endpoints|Treatments |
|
NCT05083299 |
DWAP_P401 | N/A |
Completed |
Arterial Occlusive Diseases |
2022-01-20 |
2024-10-16 |
Primary Endpoints|Treatments |
|
NCT04941196 |
BE | P1 |
Completed |
Healthy Volunteers |
2020-10-26 |
2022-09-09 |
Primary Endpoints|Treatments |
|
NCT03509922 |
YMC036 | P4 |
Completed |
Peripheral Arterial Disease|Thrombophilia |
2019-12-26 |
2024-10-16 |
Primary Endpoints |
|
NCT03947528 |
Sarpogrelate | P1 |
Unknown status |
Malnutrition |
2019-05-13 |
50% |
2024-10-16 |
Primary Endpoints|Treatments |
NCT03947489 |
Sarpogrelate | P1 |
Completed |
Healthy Volunteers |
2019-05-06 |
2024-10-16 |
Primary Endpoints |
|
NCT02959606 |
SAFE | P4 |
Unknown status |
Peripheral Arterial Disease|Peripheral Vascular Diseases |
2019-01-01 |
2024-10-16 |
Primary Endpoints|Treatments |
|
NCT01674686 |
NCT01674686 | P4 |
Unknown status |
Angina Pectoris, Variant |
2018-12-31 |
2024-10-16 |
Primary Endpoints|Treatments |
|
NCT03574285 |
DDS17-035BE | P1 |
Completed |
Healthy Volunteers |
2018-08-21 |
17% |
2024-10-16 |
Primary Endpoints|Treatments |
NCT03573622 |
DDS17-034BE | P1 |
Completed |
Healthy Volunteers |
2018-08-21 |
17% |
2024-10-16 |
Primary Endpoints|Treatments |
ChiCTR-IPR-14005534 |
ChiCTR-IPR-14005534 | N/A |
Recruiting |
Thrombosis |
2015-11-10 |
|||
CTR20171098 |
CTR20171098 | P1 |
Completed |
Chronic Pain |
2018-01-06 |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20160023 |
CTR20160023 | N/A |
Completed |
Chronic Pain |
2016-12-01 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT02607436 |
SAGE-CAD | P4 |
Completed |
Myocardial Ischemia|Coronary Artery Disease |
2016-02-01 |
2024-10-16 |
Primary Endpoints|Treatments |
|
ChiCTR-IPR-14005567 |
ChiCTR-IPR-14005567 | N/A |
Recruiting |
Thrombosis |
2015-11-10 |
|||
NCT01869881 |
SONATA Study | P4 |
Completed |
Kidney Diseases|Diabetic Nephropathy |
2014-11-17 |
2024-10-16 |
Primary Endpoints |
|
NCT02393612 |
DAVICI | P3 |
Completed |
Peripheral Vascular Diseases|Peripheral Arterial Disease |
2014-04-01 |
2024-10-16 |
Primary Endpoints |
|
NCT02097511 |
DDI-102 | P1 |
Completed |
Hypertension|Peripheral Arterial Disease |
2014-01-01 |
2024-10-16 |
Primary Endpoints |
|
CTR20130158 |
CTR20130158 | N/A |
Completed |
Chronic Pain |
2013-10-31 |
2025-04-29 |
||
NCT01548274 |
AGU-65 | N/A |
Unknown status |
Atherosclerosis |
2012-10-01 |
2024-10-16 |
Primary Endpoints|Treatments |
|
NCT02294643 |
SERENADE | P3 |
Completed |
Coronary Artery Disease|Kidney Failure, Chronic |
2012-03-01 |
2024-10-16 |
Primary Endpoints |
|
NCT01841086 |
KUP-SPG3-101 | P1 |
Completed |
Healthy Volunteers |
2011-11-01 |
2019-03-19 |
Treatments |
|
NCT01429688 |
DP-SACL-I-003 | P1 |
Completed |
Healthy Volunteers |
2011-08-01 |
2019-03-19 |
Treatments |